OPM announces positive interim results of its Phase 1 study

OPM announces positive interim results of its Phase 1 study evaluating OPM-101 in healthy volunteers

Dijon, France, October 2, 2023, at 6:00 pm CEST – Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, announces positive interim results at the end of the first part of the Phase 1 single-ascending-dose oral administration (SAD) study of its drug candidate OPM-101 in healthy volunteers.